ClinicalTrials.Veeva

Menu

Prognosis of Paroxysmal Kinesigenic Choreoathetosis in Korea

Seoul National University logo

Seoul National University

Status

Enrolling

Conditions

Paroxysmal Kinesigenic Choreoathetosis

Study type

Observational

Funder types

Other

Identifiers

NCT04023656
1611HJKim808

Details and patient eligibility

About

The aim of this study is to assess the prognosis of paroxysmal kinesigenic choreoathetosis (PKC) in Korean.

Full description

PKC is a hyperkinetic movement disorder including dystonia, chorea, athetosis, or ballism, which are characteristically triggered by a sudden movement from rest. The prevalence of this disorder is estimated to be 1 in 150,000 population. Males are more commonly affected than females, and the age of onset is typically in childhood or adolescence. PKC is mainly a familial disorder with autosomal dominant inheritance and incomplete penetrance, but it can occur sporadically. The PRRT2 (proline-rich transmembrane protein 2) gene is believed to be the major causative gene.

The prognosis of PKC is usually favorable. The severity and frequency of the attacks are reduced by anticonvulsant medication such as carbamazepine, and the number of the attacks decreases at the age of 20-30 years. However, there has been little study of long-term prognosis of PKC, and no study has been conducted in Korean population.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female PKC patients who were18 years of age and older
  • Subjects were diagnosed as paroxysmal kinesigenic choreoathetosis (PKC)
  • Subjects were enrolled voluntarily and understood the contents of this trial

Exclusion criteria

  • Existence of lesions on the brain
  • Existence of neurological deficit that suspected lesions on the brain
  • Existence of epileptiform discharges on electroencephalogram
  • Subjects with secondary PKC which was caused by other disorder or illness
  • Existence of illness or problems which made difficult to be enrolled to this trial judged by clinicians

Trial contacts and locations

1

Loading...

Central trial contact

Han-joon Kim, MD, Ph.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems